nach oben

Current Infectious Disease Reports

Erschienen in:

01.02.2012 | HIV/AIDS (RD MacArthur, Section Editor)

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

verfasst von: Alice Tseng, Michelle Foisy

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Advances in antiretroviral therapy have turned HIV into a chronic, manageable disease. Patients often require treatment for co-morbid conditions as well as HIV, and consequently, pharmacokinetic interactions between antiretrovirals (ARVs) and other drug classes are an increasing concern. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors are involved in the CYP450 or other transporter systems, and may be associated with higher risk of clinically significant drug interactions. One reverse transcriptase inhibitor, abacavir, has demonstrated weak inhibition of CYP3A4, 2D6 and 2C9 in vitro, but is not associated with any clinically significant interactions involving the CYP450 system. The integrase inhibitor raltegravir is not involved in the CYP450 system, and may be a suitable option to use when trying to minimize interactions with other drug classes. This review summarizes recently published data on clinically significant drug interactions between ARVs and other drug classes including antineoplastics, immunosuppressant transplant drugs, directly acting antivirals for hepatitis C, antifungals, antimalarials, corticosteroids, psychotropics, hormonal contraceptives, anticoagulants, drugs for pulmonary hypertension, and herbal products. In situations of suspected or potential interactions, close monitoring is warranted, and dose adjustments or substitutions may be required.

Buchacz K, Baker RK, Palella FJJ, et al. AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS. 2010;24(10):1549–59.PubMedCrossRef

Vance DE, Mugavero M, Willig J, et al. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2010;May 13. [Epub ahead of print].

Evans-Jones JG, Cottle LE, Back DJ, et al. Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2010;50(10):1419–21.PubMedCrossRef

Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413–23.PubMedCrossRef

• Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol. 2009;21:445–54. Comprehensive review on this topic.PubMedCrossRef

• Makinson A, Pujol J-L, Le Moing V, et al. Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol. 2010;5(4):562–71. Comprehensive review on this topic. PubMedCrossRef

Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin’s lymphoma. AIDS. 2010;24(15):2408–12.PubMed

Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):E22–5.PubMedCrossRef

Mir O, Dessard-Diana B, Louet AL, et al. Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients. Br J Clin Pharmacol. 2010;69(1):99–101.PubMedCrossRef

10.

Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol. 2011; Jan 5 [Epub ahead of print].

11.

Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol. 2004;27(1):81–4.PubMedCrossRef

12.

Desnoyer A, Al Kaied F, Descamps D, et al. Deleterious pharmacokinetic interaction between bexarotene and efavirenz. AIDS. 2010;24(14):2296–8.PubMedCrossRef

13.

Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother. 2010;44:377–82.PubMedCrossRef

14.

Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother. 2010;65(5):999–1004.PubMedCrossRef

15.

Tsapepas DS, Webber AB, Aull MJ, et al. Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. Am J Health Syst Pharm. 2011;68(2):134–42.CrossRef

16.

Moreno-Zamora A, Pérez-Elías MJ, Casado JL, et al. Safety (specially renal) and antiretroviral activity or raltegravir-based HAART in HIV-subjects after solid organ transplantation [abstract]. XVIII International AIDS Conference, July 18–23, 2010, Vienna, Austria.

17.

Miro J, Manzardo C, Brunet M, et al. Combination of RAL + 3TC or FTC + ABV or TDF is safe, effective, and prevents pharmacokinetic interactions with immunosuppressive drugs in HIV-1-infected solid organ transplant recipients [abstract 644]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA.

18.

Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos. 2011;39(3):510–21.PubMedCrossRef

19.

Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27–Mar 2, 2011, Boston, USA.

20.

Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Cambridge, MA 2011.

21.

Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother. 2010;65:1079–85.PubMedCrossRef

22.

Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother. 2007;18(3):163–7.PubMed

23.

Schering Corporation a subsidiary of Merck & Co. Victrelis (boceprevir) Product Monograph. Whitehouse Station, NJ 2011.

24.

Van Heeswijk RPG, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27–Mar 2, 2011, Boston, USA.

25.

Garg V, Luo X, McNair L, et al. Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 629]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27–Mar 2, 2011, Boston, USA.

26.

• Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf. 2010;9(5):723–42. Comprehensive review on this topic.PubMedCrossRef

27.

Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80:126–35.PubMedCrossRef

28.

Pfizer Canada Inc. Vfend (voriconazole) Product Monograph. Kirkland, Quebec 2010.

29.

Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother. 2008;42(5):698–703.PubMedCrossRef

30.

Toy J, Giguère P, Kravcik S, la Porte CJ. Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia. AIDS. 2011;25(4):541–2.PubMedCrossRef

31.

Brüggemann RJM, van Luin M, Colbers EPH, et al. Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers. J Antimicrob Chemother. 2010;65(10):2188–94.PubMedCrossRef

32.

Soyinka JO, Onyeji CO, Owolabi AR, et al. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol. 2010;69(3):262–70.PubMedCrossRef

33.

Soyinka JO, Omoruyi SO, Adegbenga RS, et al. Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. J Pharm Pharmacol. 2009;61:439–43.PubMedCrossRef

34.

Ridtitid W, Wongnawa M, Mahatthanatrakul W, et al. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000;52:1265–8.PubMedCrossRef

35.

Van Luin M, Van der Ende ME, Richter C, et al. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS. 2010;24(8):1223–6.PubMedCrossRef

36.

Le Bel J, Abgrall S, Laouenan C, et al. Lack of pharmacokinetic interaction between doxycycline and protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV patients [abstract P_15]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13–15, 2011, Miami, USA.

37.

• Foisy MM, Yakiwchuk EMK, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9(6):389–96. Comprehensive review on this topic, including recommendations on clinical management.PubMedCrossRef

38.

Valin N, De Castro N, Garrait V, et al. Cushing’s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. J Int Assoc Physicians AIDS Care (Chic). 2009;8(2):113–21.CrossRef

39.

Health Canada. Health Canada Public Safety Information. Available from: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/fluticasone_ritonavir_pa-ap_e.pdf, accessed May, 2011.

40.

Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009;6:10.PubMedCrossRef

41.

Yombi JC, Maiter D, Belkhir L, et al. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008;27 Suppl 2:S79–82.PubMedCrossRef

42.

Danaher PJ, Salsbury TL, Delmar JA. Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir. Orthopedics. 2009;32(6):450.PubMedCrossRef

43.

Ramanathan R, Pau AK, Busse KH, et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. Clin Infec Dis. 2008;47(12):e97–9.CrossRef

44.

Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing’s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010;47(7):830–1.PubMedCrossRef

45.

Gray D, Roux P, Carrihill M, Klein M. Adrenal suppression and Cushing’s syndrome secondary to ritonavir and budesonide. S Afr Med J. 2010;100(5):296–7.PubMed

46.

Frankel JK, Packer CD. Cushing’s syndrome due to antiretroviral-budesonide interaction. Ann Pharmacother. 2011;45:May 10 [Epub ahead of print].

47.

Molloy A, Matheson NJ, Meyer PAR, et al. Cushing’s syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. AIDS. 2011;25:1337–9.PubMedCrossRef

48.

Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29(11):1386–91.PubMedCrossRef

49.

Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett. 2010;4(1):7–8.PubMedCrossRef

50.

Geraci MJ, McCoy SL, Crum PM, Patel RA. Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction. Int J Emerg Med. 2010;3(2):81–4.PubMedCrossRef

51.

Burger DM, Jacobs BS, Colbers A, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers [abstract P_10]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13–15th, 2011, Miami, USA.

52.

Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002;22(4):366–70.PubMedCrossRef

53.

Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol. 2010;66(10):977–85.PubMedCrossRef

54.

Baker J, Rainey PM, Moody D, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir. Am J Addict. 2010;19(1):17–29.PubMedCrossRef

55.

McCance-Katz EF, Moody DE, Morse GD, et al. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict. 2010;19(1):30–7.PubMedCrossRef

56.

Bruce RD, Altice F, Moody D, et al. Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2010;54:511–4.PubMedCrossRef

57.

Sekar V, Tomaka F, Lefebevre E, et al. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenace therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol. 2011;51(2):271–8.PubMedCrossRef

58.

El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care. 2008;13(2):123–32.PubMedCrossRef

59.

Tackett D, Child M, Agarwala S, et al. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects [abstract 543]. 10th Conference on Retroviruses and Opportunistic Infections, February 10–14, 2003, Boston.

60.

Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011;16(2):157–64.PubMedCrossRef

61.

U.S. Food and Drug Administration. Important updates to the Reyataz (atazanavir) label April 30, 2009; Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm121639.htm, accessed May 17, 2011.

62.

Bristol-Myers Squibb Canada. Reyataz (atazanavir) Product Monograph. Montreal, QC 2011.

63.

Abbott Laboratories Limited Canada. Kaletra (lopinavir/ritonavir) Prescribing Information. Canada: Saint Laurent; 2010.

64.

Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG Trial A5188. J Acquir Immune Defic Syndr. 2010;55(4):473–82.PubMedCrossRef

65.

Carten M, Kiser J, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel, and efavirenz [abstract 934]. 17th Conference on Retroviruses and Opportunistic Infections, February 16–19, 2010, San Francisco, CA.

66.

Sevinsky H, Eley T, He B, et al. Effect of efavirenz on the pharmacokinetics of ethinyl estradiol and norgestimate in healthy female subjects [A-958]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.

67.

Lakhi N, Govind A. Implanon® failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Health Care. 2010;36(3):181.PubMedCrossRef

68.

Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002;29:471–7.PubMed

69.

Stuart G, Moses A, Corbett A, et al. Pharmacokinetic and pharmacodynamic activity of the combined oral contraceptives in HIV+ women in Lilongwe, Malawi [abstract 637]. 18th Conference on Retroviruses and Opportunistic Infections, Feb 27–Mar 2, 2011, Boston, USA.

70.

Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther. 2007;81(2):222–7.PubMedCrossRef

71.

Anderson MS, Hanley WD, Moreau A, et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol. 2011;71(4):616–20.PubMedCrossRef

72.

German P, Wang M, Warren D, Kearney BP. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and elvitegravir/cobicistat/emtricitabine/tenofovir single tablet regimen [abstract O_17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy, April 13–15th, 2011, Miami, USA.

73.

Welzen MEB, Van den Berk GEL, Hamers RL, Burger DM. Interaction between antiretroviral drugs and acenocoumarol. Antiviral Ther. 2011;16:249–52.

74.

Beinema M, Brouwers JRBJ, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost. 2008;100:1052–7.PubMed

75.

Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interaction involving warfarin: practice toll and practical management tips. Can Pharm J. 2011;144(1):21–5.CrossRef

76.

• Liedtke MD, Rathbun RC. Drug interactions with antiretrovirals and warfarin. Expert Opin Drug Saf. 2010;9(2):215–23. These authors provide a timely overview on this topic.PubMedCrossRef

77.

Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach. Clin Microbiol Infect. 2011;17(1):25–33.PubMedCrossRef

78.

• Hardy H, Backman ES, Farber HW. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. Pharmacotherapy. 2010;30(4):139e–44e. Includes a summary of pharmacokinetic characteristics of PAH agents and discusses implications for interactions with antiretrovirals.PubMedCrossRef

79.

Acetelion Pharmaceuticals Ltd. Tracleer (bosentan) Product Monograph. Laval, QC 2010.

80.

Weiss J, Herzog M, Haefeli WE. Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. Eur J Clin Pharmacol. 2011;660(2–3):298–304.

81.

Dingemanse J, van Giersbergen PL, Patat A, Nilsson PN. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir Ther. 2010;15(2):157–63.PubMedCrossRef

82.

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Federal register. October 14, 2011. p. 1–167. Up to date guidelines on HIV treatment.

83.

Beau-Salinas F, Garot D, Le Guellec C, et al. Possible reduction in indinavir serum concentrations by bosentan. Ther Drug Monitor. 2005;27(6):822–3.CrossRef

84.

Loulergue P, Gaillard R, Mir O. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir. Scand J Infect Dis. 2011;43(3):239–40.PubMedCrossRef

85.

Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011;50(1):25–39.PubMedCrossRef

86.

Littlewood RA, Vanable PA. Complementary and alternative medicine use among HIV-positive people: research synthesis and implications for HIV care. AIDS Care: Psychological and Socio-medical Aspects of AIDS/HIV. 2008;20(8):1002–18.

87.

• van den Bout-van den Beukel CJP, Koopmans PP, van der Ven AJAM, et al. Possible drug metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev. 2006;38:477–514. Very comprehensive overview of this topic.PubMedCrossRef

88.

van den Bout-van den Beukel CJP, Bosch MEW, Burger D, et al. Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications. AIDS. 2008;22(10):1243–4.CrossRef

89.

Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy. 2010;30(8):797–805.PubMedCrossRef

90.

Molto J, Valle M, Miranda C, et al. Herb-drug Interaction between echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother. 2011;55:326–30.PubMedCrossRef

91.

Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9(8):1946–52.PubMedCrossRef

92.

• Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother. 1997;31:1040–58. The authors provide a detailed algorithm for predicting, assessing, and managing potential interaction in HIV that are relevant for clinicians.PubMed

93.

Sheehan NL, Kelly DV, Tseng AL, et al. Evaluation of HIV drug interaction web sites. Ann Pharmacother. 2003;37:1577–86.PubMedCrossRef

94.

• Krakower D, Kwan CK, Yassa DS, Colvin RA. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis. 2010;51(7):813–22. The authors provide a comprehensive review of reliable and current internet resources for HIV clinicians.PubMedCrossRef

95.

Van Heeswijk R, Gysen V, Googaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir [abstract A-966]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.

96.

Zacà V, Metra M, Danesi R, et al. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther Adv Respir Dis. 2009;3(1):11–4.PubMedCrossRef

97.

Durant J, Dellamonica P, Garraffo R, et al. The effect of tipranavir/ritonavir on the pharmacokinetics of tadalafil in healthy volunteers [abstract 61]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, April 16–18, 2007, Budapest, Hungary.

Titel: Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs
verfasst von: Alice Tseng
Michelle Foisy
Publikationsdatum: 01.02.2012
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0229-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Gastrointestinal Infections in the Setting of Natural Disasters

Roles of Zinc in the Pathophysiology of Acute Diarrhea

Cholera: Lessons from Haiti and Beyond

Diagnosis, Treatment, and Prevention of Anal Cancer

Molecular Diagnosis of Diarrhea: Current Status and Future Potential

Key Concepts in the Early Immunology of HIV-1 Infection